Published in Front Comput Neurosci on October 23, 2013
Basal ganglia: physiological, behavioral, and computational studies. Front Syst Neurosci (2014) 0.76
Dopamine Replacement Therapy, Learning and Reward Prediction in Parkinson's Disease: Implications for Rehabilitation. Front Behav Neurosci (2016) 0.75
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol (1996) 7.24
Learning and memory functions of the Basal Ganglia. Annu Rev Neurosci (2002) 5.96
A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. Proc Natl Acad Sci U S A (1988) 5.25
A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci (2001) 3.56
Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol (1995) 3.35
The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord (2008) 3.30
The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol (2005) 3.28
The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci (1999) 2.65
It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci (2003) 2.44
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci (2007) 2.11
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 2.10
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 1.90
Activation of immediate early genes and memory formation. Cell Mol Life Sci (1999) 1.86
Immediate-early genes and synaptic function. Neurobiol Learn Mem (1998) 1.75
Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci (2008) 1.71
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci (2001) 1.66
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Egr transcription factors in the nervous system. Neurochem Int (1997) 1.56
Regulated transcription of the immediate-early gene Zif268: mechanisms and gene dosage-dependent function in synaptic plasticity and memory formation. Hippocampus (2002) 1.53
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Mov Disord (2007) 1.50
Changes in activity of the striatum during formation of a motor habit. Eur J Neurosci (2007) 1.47
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol (2010) 1.44
Constitutive expression of zif268 in neocortex is regulated by synaptic activity. Proc Natl Acad Sci U S A (1991) 1.43
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord (2005) 1.26
Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J (2008) 1.22
Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol (2003) 1.22
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol (2008) 1.19
The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res (2007) 1.09
Learning in sensorimotor circuits. Curr Opin Neurobiol (2004) 1.04
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology (2005) 1.00
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol (1998) 0.98
Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint. Neuroendocrinology (2001) 0.96
Motor-skill learning in a novel running-wheel task is dependent on D1 dopamine receptors in the striatum. Neuroscience (2008) 0.94
Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease. Behav Brain Res (2005) 0.92
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res (2006) 0.92
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur J Neurosci (2005) 0.91
High basal expression of the zif/268 immediate early gene in cortical layers IV and VI, in CA1 and in the corpus striatum--an in situ hybridization study. Neurosci Lett (1991) 0.89
Therapeutic value of exercise training in Parkinson's disease. Med Sci Sports Exerc (1999) 0.89
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One (2008) 0.87
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord (2009) 0.86
Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur J Pharmacol (1989) 0.85
Neurorehabilitation with neural transplantation. Neurorehabil Neural Repair (2010) 0.85
Localization of the NGFI-A protein in the rat brain. Brain Res Mol Brain Res (1990) 0.85
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation (2012) 0.84
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Eur J Neurosci (2003) 0.83
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat Disord (2009) 0.83
D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. Brain Res Mol Brain Res (1998) 0.82
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol (2013) 0.82
Molecular basis of levodopa-induced dyskinesias. Ann Neurol (2000) 0.81
Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction. Neuroscience (2008) 0.80
The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord (2000) 0.79
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Neuroscience (2013) 0.79
Exercise improves motor deficits and alters striatal GFAP expression in a 6-OHDA-induced rat model of Parkinson's disease. Neurol Sci (2012) 0.78
Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Parkinsonism Relat Disord (2009) 0.78
Parkinson's disease rehabilitation: a pilot study with 1 year follow up. Mov Disord (2010) 0.78
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res (2006) 0.77
Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist. Brain Res Mol Brain Res (1998) 0.76
Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. Eur J Pharmacol (1997) 0.76
Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats. Neuroscience (1997) 0.76
Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation. Neuroscience (1994) 0.76
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.48
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol (2010) 1.44
Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp Neurol (2003) 1.38
Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J (2011) 1.17
The clinical spectrum of late-onset Alexander disease: a systematic literature review. J Neurol (2010) 1.11
The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res (2007) 1.09
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci (2005) 1.02
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2009) 0.98
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. Neuropharmacology (2012) 0.95
Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res (2009) 0.93
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem (2008) 0.93
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol (2002) 0.92
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2003) 0.88
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotox Res (2010) 0.87
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem (2003) 0.87
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse (2002) 0.87
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology (2009) 0.85
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology (2004) 0.85
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol (2004) 0.84
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation (2012) 0.84
Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse (2001) 0.84
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse (2007) 0.83
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Neurotox Res (2009) 0.82
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg Med Chem (2004) 0.82
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol (2013) 0.82
Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res (2006) 0.82
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol (2009) 0.81
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol (2007) 0.81
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res (2009) 0.81
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol (2003) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. J Neurochem (2014) 0.81
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp Brain Res (2007) 0.80
Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. J Neurochem (2006) 0.80
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. Neurotox Res (2013) 0.80
Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology (2003) 0.80
Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. Parkinsons Dis (2012) 0.80
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology (2010) 0.80
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? Behav Pharmacol (2006) 0.80
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology (2003) 0.80
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics (2009) 0.80
New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur J Pharmacol (2005) 0.79
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. Exp Neurol (2006) 0.79
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse (2011) 0.79
Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective? Exp Neurol (2012) 0.78
Parkinson's disease rehabilitation: a pilot study with 1 year follow up. Mov Disord (2010) 0.78
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res (2010) 0.77
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. J Neurol Sci (2006) 0.77
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res (2006) 0.77
Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists. Synapse (2008) 0.76
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. Parkinsonism Relat Disord (2008) 0.76
Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacology (Berl) (2002) 0.76
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? J Neurochem (2014) 0.76
Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. Synapse (2008) 0.76
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) (2014) 0.76
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord (2013) 0.76
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem (2012) 0.76
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. Behav Pharmacol (2005) 0.75
Multiple mechanisms of neurodegeneration and progression. Prog Neurobiol (2017) 0.75
Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) (2015) 0.75
[Neuropsychological evaluation and psychological intervention on patients with Parkinson's disease in physical rehabilitation]. G Ital Med Lav Ergon (2014) 0.75
Disexecutive functions and depression in patients with Parkinson disease: the impact on rehabilitation outcome. Am J Phys Med Rehabil (2014) 0.75
Blink reflex discloses CNS dysfunction in neurologically asymptomatic patients with systemic sclerosis. Clin Neurophysiol (2004) 0.75